Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 9Topotecan 5Temozolomide 5Melphalan 5Irinotecan 5Busulfan 5fludarabine 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4liposomal doxorubicin 3fludarabine phosphate 3cabozantinib 3Vincristine 3regorafenib 2pegfilgrastim 2Sirolimus 2Doxorubicin 2Bone Marrow Transplantation 2trioctyl phosphine oxide 1trifluridine tipiracil drug combination 1thymoglobulin 1talazoparib 1selinexor 1seclidemstat 1racotumomab 1poly ICLC 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1olaparib 1niraparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Ewing × lexatumumab × Clear all
NCT00428272 2019-12-17

HGS-ETR2 to Treat Children With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
30 enrolled
CNSSarcoma

Neoplasm Metastasis, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡